Alcohol is a leading cause of liver disease worldwide. Although alcohol abstinence is the crucial therapeutic goal for patients with alcoholic liver disease, these patients have less access to psychosocial, behavioral and/or pharmacological treatments for alcohol use disorder. Psychosocial and behavioral therapies include 12-step facilitation, brief interventions, cognitive behavioral therapy, and motivational enhancement therapy. In addition to medications approved by the Food and Drug Administration (FDA) for alcohol use disorder (disulfiram, naltrexone and acamprosate), recent efforts to identify potential new treatments have yielded promising candidate pharmacotherapies. Finally, more efforts are needed to integrate treatments across disciplines toward patient-centered approaches in the management of patients with alcohol use disorder and alcoholic liver disease.
INTRODUCTION
Despite the mortality and morbidity resulting from alcohol use disorder(1), <10% of patients receive treatment for alcohol use disorder (2) . There is a paucity of clinical trials in patients with alcoholic liver disease and little integration of addiction specialists into the medical BMI and GGT to alcohol consumption. Phosphatidylethanol is an abnormal phospholipid generated from phosphatidylcholine in the presence of ethanol and is positive in blood more than 2 weeks after ethanol is cleared from the body(16). It is more sensitive than ethyl glucuronide for identification of current drinking (12) and is more sensitive compared to GGT and CDT(17) . A combination of CDT with GGT improves the sensitivity of detecting heavy drinking without loss in specificity (13) .
CLINICAL STAGES OF ALCOHOLIC LIVER DISEASE
The risk for alcoholic liver disease rises with increasing daily alcohol consumption with a threshold of 12-22 g/day in women and 24-46 g/day in men(18), however, this relationship is not dose-dependent(19). There are individual differences and risk factors, including genetic predisposition, age, gender, metabolic syndrome, diabetes, obesity, smoking, iron overload, and chronic hepatitis B or C(20, 21) that modify risk.
Alcoholic liver disease comprises several forms ranging from relatively mild and reversible steatosis (fatty liver) and alcoholic hepatitis, to fibrosis and finally cirrhosis and hepatic failure (22) . Fatty liver develops in about 90% of individuals who drink >60g/day of alcohol and is generally reversible with 4-6 weeks abstinence (23, 24) . About 25% of patients with alcohol use disorder develop alcoholic hepatitis. Treatments for alcoholic hepatitis (e.g.: prednisone and pentoxifylline) may have limited efficacy(25), which further highlights the critical importance of treating the underlying alcohol use disorder(26). The severity of alcoholic hepatitis can range from mild to severe and can be superimposed on chronic liver disease (27) . Prospective studies indicate that the recent, rather than lifetime alcohol consumption, predicts alcoholic cirrhosis (19, 28, 29) . While treatments for alcoholic liver disease have been extensively reviewed elsewhere(30-34), this review (Box 1) focuses on the treatment of the underlying problem in these patients, i.e. alcohol use disorder.
Box 1

Review Criteria
In April 2016, we searched PubMed using the following search terms: 'alcohol use disorder', 'liver disease', 'alcoholic liver disease', 'treatment'. The references from initial papers identified were searched to identify additional references. We focused only on papers written in English.
TREATMENT FOR ALCOHOL USE DISORDER IN PATIENTS WITH ALCOHOLIC LIVER DISEASE
Despite evidence that outcomes improve with integration of psychosocial and medical care(35), there are almost no randomized studies for behavioral and/or pharmacological treatments in patients with alcohol use disorder and alcoholic liver disease. Alcohol abstinence is the most important therapeutic goal for patients with alcoholic liver disease, as abstinence can improve outcome at all stages of disease(36-38).
Psychosocial and behavioral treatments
Brief interventions (Table 4 ) are a counseling strategy that can be delivered by a health care provider during a 5-10 minute medical office visit. The intervention is aimed at educating the patient about problematic drinking, increasing motivation to change behavior, and reinforcing skills to address problematic drinking (39) . In primary care settings, studies support the use of brief interventions to reduce drinking (40, 41) particularly when the intervention is repeated over multiple visits with follow-up telephone consultations (39) . Although brief interventions are not sufficient by themselves in those with very heavy use or dependence (42) , they can reinforce other therapeutic approaches such as compliance to medications (43) and/or referral to treatment programs (44, 45) . This approach is typically referred to with the acronym SBIRT: screening, brief intervention and referral to treatment(26, 46). Specific psychosocial and behavioral therapies for alcohol use disorder include 12-step facilitation, cognitive behavioral therapy (CBT), and motivational enhancement therapy (MET). Twelve-step facilitation is abstinence-based, and involves participation in Alcoholics Anonymous meetings. The program is grounded in acceptance, spirituality and moral inventories (47) . CBT focuses on identifying triggers and maladaptive behaviors that engender relapse. The approach encourages coping mechanisms to allow replacement of alcohol-laden with alcohol-free circumstances (48) . MET seeks to frame the decision to stop or modify drinking in terms of a dilemma and helps the patient work through the dilemma by "rolling with the resistance" to change (49) . Lastly, mobile phone applications are beginning to be used to support reduction in risky drinking(50).
It is not established if any of these therapies is superior. Indeed, the Matching Alcoholism Treatments to Client Heterogeneity (MATCH) trial (51) showed that they are equivalent. Similarly, the United Kingdom Alcohol Treatment Trial compared social/network therapy to MET and found no difference in outcome (52) . The large Combining Medications and Behavioral Interventions (COMBINE) study examined whether combining medications and a behavioral intervention improves drinking outcomes in patients with alcohol use disorder (53) . The intervention was a combination of all three interventions used in the MATCH trial. In addition, COMBINE tested Medical Management, an intervention that focuses on medication compliance, management of side-effects and goals toward harmful drinking reduction and/or abstinence (54) . The results showed that combination of the behavioral intervention with medications was superior to medication alone and that naltrexone combined with Medical Management can be a cost-effective way to treat alcohol use disorder (53) .
Clinical research on the use of psychosocial and behavioral treatments for alcohol use disorder in patients with liver disease is limited. A landmark study integrating treatment for both alcoholic liver disease and alcohol use disorder was conducted by Lieber and colleagues (55) . In this study, addition of a brief intervention to a pharmacologic treatment trial for liver fibrosis resulted in a significant reduction in alcohol drinking. Other studies examined behavioral approaches like CBT and MET for alcohol abstinence in patients with alcoholic liver disease and these studies were recently reviewed systematically (13 effective in maintaining abstinence, combining comprehensive medical care and behavioral approaches such as CBT and MET did increase abstinence rates. This indicates that the use of integrated care to treat alcohol use disorder in the context of alcoholic liver disease may lead to better outcomes.
Pharmacological treatments: management of alcohol detoxification
Alcohol withdrawal syndrome is characterized by a constellation of acute symptoms, which may include anxiety, tremors, nausea, insomnia, and in severe cases seizures and delirium tremens (56) . Delirium tremens may occur at any time during withdrawal, most commonly between 48-72 hours of abstinence. While up to 50% of alcoholic individuals manifest alcohol withdrawal symptoms after stopping drinking, only a small percentage requires medical treatment. The severity of withdrawal is typically measured with ranked scales such as the Clinical Institute Withdrawal Assessment for Alcohol-revised (CIWA-Ar) ( Table 5 ) (57). While CIWA-Ar scores ≥8 but ≤15 indicate a potential need for a pharmacological treatment, an alcohol withdrawal syndrome with a CIWA-Ar score >15 must be treated pharmacologically. Benzodiazepines are the mainstay of treatment as they are the only class of medications that reduces the risk of withdrawal seizures and/or delirium tremens.
In alcoholic patients with alcoholic liver disease, lorazepam or oxazepam are preferred as they do not undergo phase I biotransformation, rather, undergo only glucuronidation which is preserved even if liver function is compromised. Benzodiazepines may be administered on a fixed or symptom-triggered schedule. In patients with alcohol use disorder and liver disease, a symptom-triggered schedule (i.e. only when symptoms exceed a threshold of severity) is preferred, with assessment at least every 4 hours or more frequently if withdrawal symptoms are present. This strategy requires close and expert monitoring to ensure appropriate medication is provided and is preferable as it avoids unnecessary dosing of sedative hypnotic medication. Finally, it is important to distinguish withdrawal symptoms from those of alcohol intoxication or hepatic encephalopathy as benzodiazepines should not be administered in the latter cases. Other factors to consider are supportive care including fluid and electrolyte balance. Caution is needed in preventing the precipitation of Wernicke's encephalopathy, especially in those patients with end-stage liver disease who present with encephalopathy. Since prolonged glucose supplementation without the addition of thiamine can be a risk factor for the development of Wernicke's encephalopathy, thiamine supplementation should be given promptly (58) .
Pharmacological treatments to promote abstinence and prevent relapse
Consistent with the increasing knowledge of the neurobiology of addictions(3, 4), medications have been developed ( alcohol use disorder. Among them, the most promising are baclofen, gabapentin, ondansetron, topiramate and varenicline (59) .
There is, however, a lack of formal clinical trials that have tested the role of pharmacotherapies in patients with alcohol use disorder and alcoholic liver disease (26). Although hepatotoxicity with naltrexone is rare(61), naltrexone could induce liver injury and is contraindicated in patients with liver diseases as specified in an FDA ''black box"(26).
Acamprosate has not formally been tested either in patients with alcoholic liver disease, however it is the preferable FDA-approved medication in this population as it does not undergo hepatic metabolism; there are no reports of hepatotoxicity.
Baclofen, gabapentin, ondansetron, topiramate and varenicline have no evidence of liver toxicity, therefore they might also be useful in patients with alcohol use disorder and alcoholic liver disease (see Table 6 for details). However, only baclofen has been formally tested in patients with alcohol use disorder and clinically significant alcoholic liver disease in a randomized controlled trial (62, 63) and in observational studies (64, 65) ; as such, although further research with baclofen is needed, its potential utility for treatment of alcohol use disorder in hepatology settings has been highlighted (66, 67) . Unexplored are the combinations of pharmacotherapies and behavioral treatments and of different medications in patients with alcohol use disorder and alcoholic liver disease.
Liver Transplantation
Liver transplantation represents a life-saving treatment for patients with end-stage liver disease. Patients with alcohol use disorder must demonstrate 6 months' abstinence to be placed on a liver transplant waiting list. Relapse to drinking results in removal from the list with the requirement to demonstrate another 6 months' abstinence for relisting, a timeframe that is often incompatible with the prognosis of these patients. While 6 months abstinence is commonly required, few transplant programs include treatment programs for alcohol use disorder (68) . One-year relapse rates range from 67 to 81%(69) in patients with alcoholic liver disease therefore, effective, ongoing rehabilitation for alcohol addiction is necessary to achieve sustained abstinence (70) . Of note, liver transplantation without the 6-month abstinence requirement has been used to treat patients with severe, acute alcoholic hepatitis who fail to respond to steroid therapy (71, 72) . Liver transplantation in this population results in long-term survival benefits with recidivism to drinking at rates comparable or below those liver transplant patients who were required to have 6 months abstinence. For an extensive review on the management of alcohol use disorder in patients requiring liver transplant, see (68) .
SHIFTING CLINICAL LANDSCAPE: COMORBIDITIES IN PATIENTS WITH ALCOHOL USE DISORDER AND ALCOHOLIC LIVER DISEASE
There is a shifting clinical landscape of alcoholic liver disease which includes a younger age at presentation and increasing comorbid obesity (73) . By contrast, with the emergence of efficacious direct acting antiviral (DAA) drugs for Hepatitis C (HCV)(74), the comorbid etiology of alcohol use disorder and HCV will diminish in importance. Alcohol can be a singular etiology of liver disease or can be one of several etiologies, as is the case for example, with comorbid viral hepatitis and/or obesity-related non-alcoholic steatohepatitis.
Comorbidity of HCV and alcohol confers a poorer prognosis (20). HCV is the most common blood borne pathogen in the US with an estimated 2.7 million persons living with chronic HCV infection (75) . The prevalence of HCV is 3-to 30-fold higher in alcoholic individuals compared with the general population (76) . Alcoholism represents an independent risk factor for HCV infection (77, 78) . Concomitant alcohol use accelerates HCV disease progression. While the threshold level of drinking responsible for this progression is not wellestablished(20), the two conditions have a synergistic effect (79) . As a consequence, there are no safe levels of alcohol consumption in HCV-infected individuals, therefore alcohol abstinence is necessary for optimal treatment of HCV infection, especially in this new era of effective treatments for HCV.
Alcohol-induced symptoms of depression, anxiety, and insomnia are common and often indistinguishable from a primary psychiatric disorder (80) . However, these abate with abstinence, usually within a month, though there is a protracted abstinence syndrome that can persist for months (81) . Treatment for these symptoms is sometimes required. This may be particularly challenging in those patients with alcohol use disorder and HCV infection who are taking DAAs, which are substrates as well as inhibitors of cytochrome P450 3A4 and P-glycoprotein. There are clinically important drug-drug interactions between these drugs and common medications used to treat withdrawal (e.g., alprazolam; midazolam), sleep problems (e.g., zolpidem; trazodone), and psychiatric symptoms (e.g., escitalopram; St John's Wort; carbamazepine)(82).
Finally, obesity increases risk for all stages of alcoholic liver disease (83) . Prospective cohort studies show that alcohol use disorder and obesity exert a greater than additive effect on development of liver disease and share a common pathophysiology (84) . Treating alcohol use disorder in obese patients with liver disease and obesity will be integral to the management of these patients. As HCV decreases in importance as an etiology for liver disease (85) , alcohol use disorder and non-alcoholic steatohepatitis will be the most common etiologies for end-stage liver disease. As such, patients with alcohol use disorder will be prominent among those seen in hepatology practices.
CONCLUSIONS
Alcohol abstinence represents the cornerstone in the treatment of alcoholic liver disease. The clinical literature summarized here indicates that treatments for patients with alcoholic liver disease exist and providing these treatments is critical. To this end, it is important to educate physicians in addiction medicine (86) . The National Institute on Alcohol Abuse and Alcoholism has developed several professional education materials for health care providers(87). Figure 1 outlines multimodal treatments based on the severity of alcoholic liver disease.
These treatment approaches for alcohol use disorder help patients, including those with alcoholic liver disease, reduce alcohol consumption, achieve abstinence and prevent relapse. Integration of addiction medicine into the multidisciplinary teams that care for these patients may improve outcomes. 
a.
A need for markedly increased amounts of alcohol to achieve intoxication or desired effect
b.
A markedly diminished effect with continued use of the same amount of alcohol
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Withdrawal, as manifested by either of the following:
a.
The characteristic withdrawal syndrome for alcohol (refer to criteria A and B of the criteria set for alcohol withdrawal)
b.
Alcohol (or a closely related substance, such as a benzodiazepine) is taken to relieve or avoid withdrawal symptoms
The presence of at least 2 of these symptoms indicates an Alcohol Use Disorder (AUD).
The severity of the AUD is defined as:
The presence of 2 to 3 symptoms Leggio and Lee Page 22 Table 6 FDA-approved medications and others tested in alcohol use disorder patients 
